

Twelfth
Annual Report & Accounts

Financial Year
2021-2022

Solitaire Drugs & Pharma Private Limited
CIN: U24232DL2011PTC214744

Solitaire Drugs & Pharma Private Limited

Directors

Avnish Kumar Jain (DIN: 00412597)

Mukta Jain (DIN: 01797239)

Sulabh Jain (DIN: 03429718)

Statutory Auditors

U.SHANKER & ASSOCIATES

Chartered Accountants

Add.: 303, Vikas Surya Shopping Mall Manglam Place,
Sector 3 Rohini, Delhi - 110085

Registered office:

304, Vikas Surya Shopping Mall,
Sector - 3, Rohini,
Delhi- 110085, India

Plant Location

Plot No. 439 & 440, Shree Developers,
Industrial Estate, MahuaKheraGanj,
Kashipur, Uttarakhand

Solitaire Drugs &Pharma Private Limited

Regd. Add.: 304, Vikas Surya Shopping Mall, Sector - 3, Rohini, Delhi- 110085
CIN : U24232DL2011PTC214744, Email : ifreezefoods@gmail.com, Tel : 011-47501660

NOTICE

Notice is hereby given that the 12th Annual General Meeting of the Members of the Company will be held on Thursday, 29th September, 2022 at 9:30A.M. at its registered office of the Company situated at 304, Vikas Surya Shopping Mall, Sector - 3, Rohini, Delhi- 110085 to transact the following businesses:


ORDINARY BUSINESSES:-

1. To receive, consider and adopt the Audited Financial Statements including Balance Sheet, Statement of Profit and Loss Account and Cash Flow Statement for the year ending March 31, 2022 and the report of the Board of Directors and Auditors thereon.
2. To re-appoint M/s U.SHANKER & ASSOCIATES, Chartered Accountants as Statutory Auditors of the Company and to fix their remuneration and to pass the following resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 139, 142 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit & Auditors) Rules, 2014, as amended from time to time (including any statutory modification(s) or re-enactment for the time being in force), consent of the shareholders of the Company be and is hereby accorded for the re-appointment of M/s U.SHANKER & ASSOCIATES, Chartered Accountants (Firm Registration No. 014497N), as statutory auditors for the audit of the Financial Statements (including Consolidated Financial Statements) of the Company to hold office for one financial year starting from the conclusion of this Annual General Meeting held for financial year 2021-22 till the conclusion of the Annual General Meeting to be held for financial year 2022-23 at such remuneration as may be fixed by the Board of Directors".

RESOLVED FURTHER THAT any Directors of the Company be and is hereby authorized to do all such acts, deeds and things as may be considered necessary & incidental or expedient thereto for giving effect to the aforesaid resolution."

By Order of the Board
For Solitaire Drugs & Pharma Private Limited


Avnish Kumar Jain
Director
DIN- 00412597

Place: New Delhi
Dated: 05.09.2022

NOTES:

- i. A Member entitled to attend and vote at the meeting is entitled to appoint a proxy to attend and vote on poll instead of himself and that the proxy need not be a member of the company. The proxies to be effective should be deposited at the registered office of the Company not less than 48 hours before the commencement of the meeting. A blank proxy form is attached.
- ii. Copies of Directors' report and Auditors' report, Statement of Profit and Loss, Cash Flow Statement and Balance Sheet together with notes to financial statements of the Company are enclosed.
- iii. **Inspection of Documents:** Documents referred to in the Notice are open for inspection at the registered office of the Company on all working days except Saturdays and Sundays between 11:00 A.M. and 02:00 P.M. up to the date of Annual General Meeting.
- iv. Members are requested to notify immediately any change in their addresses to the Company at its Registered Office.
- v. Corporate Members intending to send their authorised representative(s) to attend the meeting are requested to send a certified copy of the Board Resolution authorising their representative(s) to attend and vote on their behalf at the Annual General Meeting as required under section 113 of the Companies Act, 2013.
- vi. Members / proxies should bring duly filled Attendance Slip enclosed to attend the meeting.
- vii. Route Map of the venue of the meeting has not been given the Company being 100% share held by promoters.

Form No. MGT-11

Proxy form

[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]

CIN: U24232DL2011PTC214744

Name of the Company: SOLITAIRE DRUGS & PHARMA PRIVATE LIMITED

Registered Office: 304, VIKAS SURYA SHOPPING MALL SECTOR- 3, ROHINI DELHI 110085

Name of the members (s):

Registered address:

E-Mail Id:

Folio No/Client Id:

DP ID:

I/We, being the member (s) of shares of the above named Company, hereby appoint

1. Name:
Address:
E-mail Id:
Signature:....., or failing him.
2. Name:
Address:
E-mail Id:
Signature:, or failing him
3. Name:
Address:
E-mail Id:
Signature:, or failing him

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 12th Annual General Meeting of the Company will be held on Thursday, 29th September, 2022 at 9:30A.M.at its registered office of the Company situated at 304, Vikas Surya Shopping Mall, Sector - 3, Rohini, Delhi- 110085 and at any adjournment thereof in respect of such resolutions as are indicated below:

1. To receive, consider and adopt the Audited Financial Statements of the Company for the year ended 31st March, 2022 along with the report of Independent Auditor's and Director's thereon.
2. Re-appointment of Statutory Auditors of the Company.

Signed this.....day of.....2022

Affix Revenue Stamp

Signature of shareholder

Signature of Proxy holder(s)

Note:

This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the meeting.

ATTENDANCE SLIP

12th Annual General Meeting

Reg. Folio:.....

No. of Shares Held:.....

Full Name of Shareholder

Full Name of Proxy/ Authorised Representative

I hereby record my presence at the 12th Annual General Meeting of the Company to be held on Thursday, 29th September, 2022 at 9:30 A.M. at its registered office of the Company situated at 304, Vikas Surya Shopping Mall, Sector - 3, Rohini, Delhi- 110085 and at any adjournment thereof.

Signature of shareholder/ proxy/ Authorised Representative

Note:

1. Please fill in this attendance slip and hand it over at the venue.
2. Members/Proxy Holders are requested to show their Photo ID Proof for attending the Meeting.

* Strike out whichever is not applicable.

DIRECTOR'S REPORT

To,
 The Members,
 Solitaire Drugs & Pharma Private Limited

The Directors of your company are pleased to present the 12th Annual Report on the business of the Company and Audited Balance Sheet for the year ending March 31, 2022, Statement Profit & Loss Account and Cash Flow Statement along with the notes and schedules for the year ended on that date.

1. COMPANY SPECIFIC INFORMATION

1.1 FINANCIAL SUMMARY AND HIGHLIGHTS

The Company's financial summary for the year under review along with previous year's figures is given hereunder:

₹ in hundred

Particular	Current Financial Year (2022)	Previous Financial Year (2021)
Revenue from Operations	34,02,886.89	21,75,310.53
Other Income	2,238.98	840.91
Profit/ Loss before Depreciation, Finance Costs, Exceptional Items and Tax Expenses	283222.13	253572.84
Less: Depreciation/ Amortization/ Impairment	46,736.61	46,312.62
Profit/ (Loss) before Finance Costs, Exceptional items and Tax Expenses	2,36,485.52	2,07,260.22
Less: Finance Costs	1,78,431.85	1,63,427.59
Profit/ (Loss) before Exceptional items and Tax Expense	58,053.67	43,832.63
Add/(Less): Exceptional Items	(48,717.08)	0
Profit/ (Loss) before Tax Expenses	9,336.59	43,832.63
Less :- Current Tax	18,000.77	11,532.23
Profit/ (Loss) after Tax Expenses	(8,664.18)	32,300.40
Less: Deferred tax	(2,169.59)	28,992.95
Profit/ (Loss)for the year (1)	(6,494.59)	3,307.45

Total Comprehensive Income/ Loss (2)	0	0
Total (1+2)	(6,494.59)	3,307.45
Balance of Profit/ (Loss) for earlier years	1,84,995.78	1,81,688.33
Less: Transfer to Capital Redemption Reserves	0	0
Less: Interim Dividend	0	0
Less: Dividend Distribution Tax	0	0
Less: Utilised for buyback of equity shares	0	0
Less: Buyback Tax	0	0
Balance Carried forward	1,78,501.19	1,84,995.78

The highlights of the Company's performance are as under:-

- Revenue from operations has been increased from Rs. 21,75,31,053/- in the previous Financial Year 2020-21 to Rs.34,02,88,689/- in the Current Financial Year 2021-2022.
- Other income has been increased from Rs. 84,091/- in the previous Financial Year 2020-21 to Rs. 2,23,898/- in the Current Financial Year 2021-2022.
- Earnings per share decreased from Rs. 1.39/- in the previous Financial Year 2020-21 to Rs. (2.73)/- in the Current Financial Year 2021-2022.

The Company is focussing on growth and achieving profitability along with a renewed commitment to enhance quality and to reduce costs. Innovations, investment and positive modifications are expected in the near future.

1.2 AMOUNT, IF ANY, WHICH THE BOARD PROPOSES TO CARRY TO ANY RESERVES

There is no amount proposed to be transferred to any reserve during the financial year ended 31st March, 2022. The balance of Reserve & Surplus at the end of the financial year is Rs. 5,24,64,119/-

1.3 DIVIDEND

In view of the loss incurred, your Directors have not recommended any dividend for the financial year ended 31st March, 2022.

1.4 MAJOR EVENTS OCCURRED DURING THE YEAR

a) State of the Company's affairs

The Company is mainly engaged in the agribusiness project of processing & preserving Fruits & Vegetables into frozen through Individual Quick Frozen (IQF) technology.

b) Change in the Nature of Business

During the year under consideration, there was no change in the nature of the business.

c) Material changes and commitments

No significant material changes and commitments have occurred between the date of the balance sheet and the date of the audit report.

1.5 DETAILS OF REVISION OF FINANCIAL STATEMENT OR THE REPORT

The Company has not revised its financial statement or the Report in respect of any of the preceding three financial years either voluntarily or pursuant to the order of any judicial authority.

2. GENERAL INFORMATION

Overview of the industry and Important changes in the industry during the last year, External Environment and Economic Outlook:

The expansion of retail food chains, demand for frozen food, technological innovations in the packaging industry, government initiatives is the key factors contributing to the growth of the Individual Quick Freezing market during the forecast period.

The primary consideration for deep-freezing is the rate at which the temperature of the food is reduced, whether it is meat, vegetables, or baked products. Longer the freezing process takes, the more time there is for the water molecules contained in the food to come together to form large ice crystals. These can pierce the cell membranes and damage the tissue, with the result that the frozen food loses its form and structure while vitamins, nutrients, and flavors are also lost.

Growing consumer demand for ready to eat meals across the globe is propelling the individual quick freezing (IQF) industry, and the increasing availability of non-seasonal food commodities is expected to have a strong influence on the individual quick freezing (IQF) industry. Furthermore, the development and expansion of retail food chains in the advanced countries are also predicted to influence the individual quick freezing (IQF) industry significantly. Increasing government initiatives to minimize food wastage is forecasted to produce more possibilities for key players in the industry.

The benefits of this method of preparing frozen food are that the process isn't time-consuming. The exact time depends on the type of IQF freezer and the product. The short freezing prevents the formation of large ice crystals in the product's cells, which makes the product to be in its shape, color, smell, and taste after defrosting, to a far greater extent. An added advantage of IQF technology is its ability to separate units of the products during freezing, which produces higher quality product compared to block freezing. This advantage is also vital for food sustainability, as the consumer can defrost and use the exactly needed quantity. The greenhouse gas discharges during the production process are one of the main restraining aspects of the industry.

Rising consumer preference towards longer shelf-life, healthy food, and technological innovations in packaging will additionally fuel the expansion of the IQF fruits and vegetable market. Growing demand from food manufacturers to preserve food products for an extended period of your time for usage as an ingredient in final products is another primary expanding the IQF fruits and vegetable market.

Induction of strategic and financial partners during the year and Delisting of Equity Shares during the year or till the date of report:

The Company has not inducted any strategic and financial Partners during the year. The Company is a closely held unlisted private Company and its shares are not listed on any Stock Exchange. Hence there is no delisting of shares during the year or till the date of report.

3. CAPITAL AND DEBT STRUCTURE

There is no change in the Authorized Share Capital of the Company. The Issued, Subscribed and Paid up Share Capital of the Company is Rs. 2,383,000/- (i.e. 238300 shares of Rs. 10/- each). The Company has not re-classified or sub-divided its Authorised Share Capital, reduced its Share Capital, buy back any of its shares during the year under review.

During the year under review, the Company has not issued debentures, bonds or other convertible and non-convertible securities, not issued Equity Shares with Differential Rights, Sweat Equity Shares, Bonus Shares, warrants and has not granted Employee Stock Options to its employees.

The shares of the Company are not held with any Trust.

4. CREDIT RATING OF THE SECURITIES

The Company has not obtained credit rating of its securities.

5. INVESTOR EDUCATION AND PROTECTION FUND

There is no amount and shares which is required to be transferred to the Investor Education and Protection Fund by the Company.

6. MANAGEMENT

6.1 DIRECTORS AND KEY MANAGERIAL PERSONNEL

Directors

During the financial year, the board was duly constituted with Mr. Avnish Kumar Jain, Mr. Sulabh Jain, and Mrs. Mukta Jain as directors.

Mrs. Mukta Jain resigned from directorship w.e.f 05.08.2021.

Key Managerial Personnel

In compliance of the provision of section 203 of the Companies Act, 2013, the company is not required to appoint any key managerial personnel.

The Directors of the Company are not required to retire by rotation as the Company is an unlisted Private Limited Company.

6.2 INDEPENDENT DIRECTORS

There is no requirement to appoint Independent Director on the Board of the Company pursuant to Sec 149(6) of the Companies Act, 2013 (hereinafter referred to as the 'Act') read with The Companies (Appointment and Qualification of Directors) Rules, 2014.

6.3 DECLARATION BY INDEPENDENT DIRECTORS AND STATEMENT ON COMPLIANCE OF CODE OF CONDUCT

The requirement of obtaining declaration from Independent Director and statement on compliance of code of conduct prescribed in the Schedule IV of the Act does not arise as there is no requirement to appoint Independent Director.

6.4. BOARD AND GENERAL MEETINGS

BOARD MEETINGS

Following board meeting held during the year 2021-2022.

DATE OF MEETING	TOTAL NO. OF DIRECTORS	PRESENT DIRECTOR
03.05.2021	3	3
24.05.2021	3	3
31.05.2021	3	3
07.06.2021	3	3
16.06.2021	3	3
02.07.2021	3	3
05.08.2021	2	2
06.09.2021	2	2
28.10.2021	2	2
12.11.2021	2	2
22.11.2021	2	2
30.11.2021	2	2
13.12.2021	2	2
03.01.2022	2	2
19.01.2022	2	2
02.02.2022	2	2
12.02.2022	2	2
21.03.2022	2	2
31.03.2022	2	2

The intervening gap between any two Board Meetings was within the period prescribed under the Companies Act, 2013.

GENERAL MEETINGS

Further, the Annual General Meeting for the financial year 2020-21 was held on 30.11.2021. During the financial year, No Extra-Ordinary General Meeting was held.

6.5 COMMITTEE MEETINGS

The Company has not constituted any committee. Hence, there was no committee meeting during the financial year.

6.6 RECOMMENDATION OF AUDIT COMMITTEE

The provisions of Section 177 of the Companies Act, 2013 read with Rule 6 of the Companies (Meetings of the Board and its Powers) Rules, 2014 are not applicable to the Company.

6.7 COMPANY'S POLICY ON DIRECTORS APPOINTMENT AND REMUNERATION

The provisions of Section 178 of the Companies Act, 2013 read with Rule 6 of The Companies (Meetings of Board and its Powers) Rules, 2014 in regard to constitution of Nomination and Remuneration Committee are not applicable on the Company and hence the Company has not devised any policy for appointment of Directors and their remuneration including criteria for determining qualifications, positive attributes, independence of a director and other matters provided under sub- section 3 of Section 178 of the Companies Act, 2013.

6.8 BOARD EVALUATION

Being a private Company, the formal annual evaluation by the Board of its performance and that of its committees and individual Directors are not mandatory.

6.9 REMUNERATION OF DIRECTORS AND EMPLOYEES OF LISTED COMPANIES

Being an unlisted Company, the provisions laid down under Section 197(12) of the Companies Act, 2013 regarding the disclosure of particulars of employees are not applicable.

No employee is in receipt of remuneration exceeding the limits laid down under Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

6.10 REMUNERATION RECEIVED BY MANAGING/WHOLE TIME DIRECTOR FROM HOLDING OR SUBSIDIARY COMPANY

Any Director of the Company is not in receipt of any commission from the Company.

Further, the Company does not have Holding or Subsidiary Company. Also, there is no Managing Director and Whole time Director in the Company.

6.11 DIRECTORS RESPONSIBILITY STATEMENT

In accordance with the provisions of Section 134(5) of the Companies Act, 2013 the Board hereby submits its responsibility Statement:—

- a) In the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit of the company for that period;
- c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- d) the directors had prepared the annual accounts on a going concern basis; and
- e) Clause (e) of section 134(5) is not applicable as the Company is not a listed Company.
- f) the directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

6.12 INTERNAL FINANCIAL CONTROL

The provisions of Section 143(3) (i) of the Companies Act, 2013, related to adequacy of internal financial controls with reference to financial statement are not applicable on the Company.

6.13 FRAUDS REPORTED BY THE AUDITOR

There is no fraud in the Company during the F.Y. ended 31st March, 2022. This is also being supported by the report of the auditors of the Company as no fraud has been reported in their audit report for the F.Y. ended 31st March, 2022.

7. DISCLOSURES RELATING TO SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES

The Company does not have any Subsidiary Company, Associate Company or Joint venture Company.

Also, during the year under review and till the date of report, the Company has not acquired or formed any new subsidiary Company, associate Company or joint venture Company.

Further, Solitaire Infracon Private Limited is holding 26.02% Equity Capital of our company and therefore as per Companies Act 2013, we are an Associate Company of Solitaire Infracon Private Limited

8. DETAILS OF DEPOSITS

The details in regard to deposits, covered under Chapter V of the Companies Act, 2013 are mentioned hereunder:

(a)	Amount accepted during the year	Nil
(b)	Amount remained unpaid or unclaimed as at the end of the year	Nil
(c)	Default in repayment of deposits or payment of interest thereon during the year and if so, number of such cases and the total amount involved	
	i. at the beginning of the year	Not applicable
	ii. maximum during the year	Not applicable
	iii. at the end of the year	Not applicable
(d)	Details of deposits which are not in compliance with the requirements of the Act	Nil
(e)	Details of National Company Law Tribunal(NCLT)/ National Company Law Appellate Tribunal (NCLAT) orders with respect to depositors for extension of time for repayment, penalty imposed, if any	Nil
(f)	Details of amount received from a person who at the time of the receipt of the amount was a Director of the Company or relative of the Director of the Company	An amount of Rs. 5,84,70,100/-were received from the Directors and their relatives as at 31.03.2022

9. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS

During the year under review, the Company has complied with the provisions of Section 185 and 186 of the Companies Act, 2013.

The company has not given any loans, guarantees or made any investments covered under the provisions of section 185 and 186 of the Companies Act, 2013.

10. PARTICULARS OF CONTRACTS OR ARRANGEMENTS MADE WITH RELATED PARTIES

During the year under consideration, the company has entered into contract or arrangements with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 which are at arm's length transactions under third proviso thereto and also disclosed in Note No. 28 of the Financial Statements attached to and forming part of the Annual Financial Statements and stated in **Form AOC-2** which is annexed as **Annexure-I**.

11. CORPORATE SOCIAL RESPONSIBILITY(CSR)

The Company has not developed and implemented any Corporate Social Responsibility initiatives as the said provisions are not applicable to it. Thus, there is no requirement to constitute a committee, formulate the policy and spend amount on Corporate Social Responsibility.

12. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO

The details of conservation of energy, technology absorption, foreign exchange earnings and outgo are as follows:

A) Conservation of Energy:

The Company's technical department continuously monitors energy consumption in the plant and takes corrective measures for better and efficient utilization of energy.

B) Technology Absorption:

Development activities of the company are directed towards energy conservation, pollution control and quality improvement. Research and Development efforts are carried out on several areas extending from raw material purchased to dispatch of final product.

C) Foreign exchange earnings and Outgo:

Earnings	: During the year the company has received USD \$ 23711.92 (Rs.17,26, 227.78) from Govindas Gift Ltd, Mauritius against Export of goods
Outgoings	: Nil

13. RISK MANAGEMENT

The Company has a mechanism to identify, assess, monitor, and mitigate various risks to key business objectives. Major risk identified by the business and functions are systematically addressed through mitigating actions on a continuous basis.

14. DETAILS OF ESTABLISHMENT OF VIGIL MECHANISM

Disclosure & establishment of vigil mechanism pursuant to provisions of Section 177 of the Companies Act, 2013 read with Rule 7 of the Companies (Meetings of the Board and its Powers) Rules, 2014 is not required.

15. MATERIAL ORDERS OF JUDICIAL BODIES / REGULATORS

During the year under consideration no orders of any nature were passed by Regulators/Court/Tribunals against the company.

16. STATUTORY AUDITORS

In terms of Section 139, 142 and other applicable provisions of the Companies Act, 2013 and the Companies (Audit & Auditors) Rules, 2014, M/s U.SHANKER & ASSOCIATES, Chartered Accountants (FRN 014497N) was appointed as the Statutory Auditors of the Company by the Members at Annual General Meeting held on 30th November, 2021 to hold office till the conclusion of the Annual General Meeting to be held for the F.Y. 2021-22 on such remuneration and out of pocket expenses as may be decided by the Board and mutually agreed by them.

The said term of Statutory Auditors is expiring in ensuing Annual General Meeting of the Company.

Based on the recommendations of the Board and upon review of confirmations of satisfaction of criteria as specified in Section 139 and 141 of the Companies Act, 2013 read with Rule 4 of Companies (Audit & Auditors) Rules, 2014, your Company had, subject to approval of the Members at the ensuing Annual General Meeting, approved reappointment of M/s U.SHANKER & ASSOCIATES, Chartered Accountants (FRN 014497N) as Statutory Auditors for the audit of the Financial Statements (including Consolidated Financial Statements) of the Company to hold office for a period of one financial year starting from the conclusion of Annual General Meeting held for financial year 2021-22 till the conclusion of the Annual General Meeting to be held for financial year 2022-23. M/s U.SHANKER & ASSOCIATES, Chartered Accountants (FRN 014497N) have confirmed their eligibility under Section 141 of the Act, and the Rules framed thereunder, for their re-appointment as Statutory Auditors of the Company.

17. SECRETARIAL AUDIT

The provisions of Secretarial Audit were not applicable on the Company. Hence any explanation or comments on qualification, reservation or adverse remarks or disclaimer made by the Practicing Company Secretary is not required.

18. BOARD'S COMMENT ON THE AUDITORS REPORT

The Notes on financial statement referred to in the Auditors' Report are self explanatory and do not call for any further comments. The observation of auditors is suitably explained in Notes to Financial Statements. The Auditors' Report does not contain any qualification, reservation or adverse remark.

Observation made by the Statutory Auditors in their Report are self-explanatory and therefore, do not call for any further comments under section 134(3)(f) of the Companies Act, 2013.

19.COMPLIANCE WITH SECRETARIAL STANDARDS

The Company is in compliance of the Secretarial Standards with respect to the General Meetings and Meetings of the Board of Directors to the extent possible specified by the Institute of Company Secretaries of India and approved as such by the Central Government.

20. CORPORATE INSOLVENCY RESOLUTION PROCESS INITIATED UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 (IBC)

The Company has not filed any application for corporate insolvency under the IBC before the NCLT and no creditor (financial or operational) has filed any application for corporate insolvency under the IBC before the NCLT against Company.

21. IMPLEMENTATION OF ANY CORPORATE ACTION

The Company has not failed to complete or implement any corporate action within the specified time limit.

22. ANNUAL RETURN AND EXTRACTS OF ANNUAL RETURN

The web address of an Annual Return pursuant to section 134(3) (a) of the Companies Act, 2013 is not given as the Company is not having its own website. Therefore, no Web link of website relating to Annual report is being provided here pursuant to section 92(3).

The Extracts of Annual Return in Form MGT-9 as required under section 92 of the Companies Act, 2013 have been amended by MCA vide Notification dated 05.03.2021 (effective from same date) has submitted Rule 12 of Companies (Management and Administration) Rule, 2014 and with effect from the amendment Form MGT 9 is not required to be prepared from the Financial Year 2020-21 & onward.

23. DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS, COURTS AND TRIBUNALS

Directors of the Company suo -moto have applied for compounding application of offence u/s Section 96 of the Companies Act, 2013 and Rules made thereafter in the office of Regional Director for not conducting the Annual General Meeting of the Company for the financial year ended 2020 within the stipulated time due to unavoidable Circumstances.

Company and its directors has compounded with compounding of Rs. 55000/- per applicant by the Hon'ble Regional Director, Northern Region.

On 25th March, 2022 Rs. 55000/- paid by Solitaire Drugs & Pharma Private Limited "(the Company) vide SRN X10564128, On 26th March, 2022 Rs. 55000/- paid by director of the Company Mr. Avnish Kumar Jain vide SRN X10590842, On 26th March 2022 Rs. 55000/- paid by director of the Company Mrs.Mukta Jain vide SRN X10590594 and On 26th March, 2022 Rs. 55000/- paid by director of the Company Mr. Sulabh Jain vide SRN X10590750.

24. OTHER DISCLOSURES:
a) Consolidated Financial Statements

The requirement of preparing consolidated financial statements is not applicable on the Company.

b) Key initiatives with respect to Stakeholder relationship, Customer relationship, Environment, Sustainability, Health and Safety

The relations with staff and workers continued to be cordial. Our Employees are the most valuable assets of the Company. We encourage innovation, meritocracy and the pursuit of excellence.

Your Company continues to accord high priority for ensuring highest safety standards in operations at every level. Through a Safety and Health Environment, your Company has once again kept the accident to negligible during the year under review.

c) Maintenance of Cost Records

The provisions of Section 148(1) of the Companies act, 2013 regarding maintenance of cost records as specified by the Central government are not applicable on the Company, hence no disclosure is given.

25. ADDITIONAL DISCLOSURES UNDER LISTING REGULATIONS

Being a Private Company, Statement of deviation or variation, Management Discussion and Analysis Report, Certificate on compliance of conditions of Corporate Governance and Suspension of Trading are not applicable.

26. DISCLOSURE PERTAINING TO THE SEXUAL HARASSMENT OF WOMEN AT THE WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013


The Company is committed for providing and promoting a safe and healthy work environment for all its employees.

The Company has not received any complaint on sexual harassment during financial year 2021-22.

Acknowledgements

Your company takes this opportunity to thank all the Shareholders of the company for their continued support. Your directors wish to place on record their appreciation for the co-operation and support received from employees, staff and other people associated with the company and look forward for their continued support.

By Order of the Board
For Solitaire Drugs & Pharma Private Limited


Avnish Kumar Jain
Director
DIN- 00412597


Sulabh Jain
Director
DIN 03429718

Annexure I
Form No. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014).

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto.

	Particulars	
1	Details of contracts or arrangements or transactions not at arm's length basis.	
(a)	Name(s) of the related party and nature of relationship	N/A
(b)	Nature of contracts / arrangements / transactions	
(c)	Duration of the contracts / arrangements/transactions	
(d)	Salient terms of the contracts or arrangements or transactions including the value, if any	
(e)	Justification for entering into such contracts or arrangements or transactions	
(f)	date(s) of approval by the Board	
(g)	Amount paid as advances, if any:	
(h)	Date on which the special resolution was passed in general meeting as required under first proviso to section 188	
2.	Details of material contracts or arrangement or transactions at arm's length basis	
(a)	Name(s) of the related party and nature of relationship	Avnish Kumar Jain (Director of the Company)
(b)	Nature of contracts / arrangements / transactions	Rent Paid/Rent Taken
(c)	Duration of the contracts / arrangements/transactions	11 months
(d)	Salient terms of the contracts or arrangements or transactions including the value, if any:	Rs. 3,60,000/-
(e)	Date(s) of approval by the Board, if any:	03.01.2022
(f)	Amount paid as advances, if any:	--

By Order of the Board
 For Solitaire Drugs & Pharma Private Limited


 Avnish Kumar Jain
 Director
 DIN- 00412597


 Sulabh Jain
 Director
 DIN 03429718



Independent Auditor's Report

To the Members of **SOLITAIRE DRUGS & PHARMA PRIVATE LIMITED**

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the financial statements of **SOLITAIRE DRUGS & PHARMA PRIVATE LIMITED** ("the Company"), which comprise the balance sheet as at 31st March 2022, and the statement of Profit and Loss and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2022, its profit/loss and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Information other than the financial statements and auditors' report thereon

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report but does not include the financial statements and our auditor's report thereon.



Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.




Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the 'Annexure A', a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143 (3) of the Act, we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
 - d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e) On the basis of the written representations received from the directors as on 31st March, 2022 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2022 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f) In our opinion, the provision of section 143(3)(1) with regard to opinion on internal financial controls with reference to financial statements and operating effectiveness of such control is not applicable to the company.
 - g) With respect to the other matters to be included in the Auditor's report in accordance with the requirements of Sec 197(16) of the Act as amended, we report that Section 197 is not applicable to a private company. Hence reporting as per Section 197(16) is not required.
 - h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company have following pending litigations which may impact its financial position.
 - a. Solitaire Drugs & Pharma Pvt. Ltd has filed case against Coldex Logistics Pvt Ltd in MSME for recovery of Rs. 12,23,881/-
 - b. Solitaire Drugs & Pharma Pvt. Ltd has filed case against Cucu Enterprises Pvt Ltd. U/s 138 for cheque bouncing of Rs. 10,00,000/-.
 - c. Solitaire Drugs & Pharma Pvt. Ltd has filed case against P & M Spark U/s 138 for cheque bouncing of Rs. 4,81,681/-.



- ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
- iv. (a) The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(b) The management has represented, that, to the best of its knowledge and belief, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

(c) Based on such audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material mis-statement.
- v. No dividend have been declared or paid during the year by the company.

Place:-Delhi
Date: 05/09/2022
UDIN:22089919AXNUSK6717

For U.SHANKER & ASSOCIATES
Chartered Accountants
FRN: 0014497N

Uma Shanker Gupta
(Partner)
Membership No. 089919




Annexure 'A'

The Annexure referred to in paragraph 1 of Our Report on "Other Legal and Regulatory Requirements".

We report that:

- (i) (a) (A) The company has maintained proper records showing full particulars, including quantitative details and situation of its fixed assets.
(B) The Company does not have any intangible assets. Accordingly, clause 3(i)(a)(B) of the Order is not applicable to the Company.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Property, Plant and Equipment have been physically verified by the management at reasonable intervals; no material discrepancies were noticed on such verification;
- (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds, comprising all the immovable properties of land and buildings which are freehold, are held in the name of the Company as at the balance sheet date.
- (d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder.
- (ii) (a) As explained to us & on the basis of the records examined by us, in our opinion, physical verification of inventory has been conducted at reasonable intervals by the management. In our opinion, the coverage and procedure of such verification by the management is appropriate. No discrepancy of 10% or more in the aggregate for each class of inventory were noticed on physical verification of stocks by the management as compared to book records.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks or financial institutions on the basis of security of current assets during any point of time of the year. The quarterly/monthly returns or statements filed by the company with such banks or financial institutions are in agreement with the books of account of the Company.



- (iii) According to the information and explanations given to us and on the basis of our examination of the records of the company, the company has not made investments in, nor provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties during the year. Accordingly, provisions of clause 3(iii)(a), 3(iii)(b), 3(iii)(c), 3(iii)(d), 3(iii)(e) and 3(iii)(f) of the Order are not applicable to the Company.
- (iv) According to the information and explanations given to us and on the basis of our examination of the records, in respect of loans, investments, guarantees, and security, provisions of section 185 and 186 of the Companies Act, 2013 have been complied with.
- (v) The company has not accepted any deposits or amounts which are deemed to be deposits covered under sections 73 to 76 of the Companies Act, 2013. Accordingly, clause 3(v) of the Order is not applicable.
- (vi) As per information & explanation given by the management, maintenance of cost records has not been specified by the Central Government under sub-section (1) of section 148 of the Companies Act.
- (vii) According to the information and explanations given to us and on the basis of our examination of the records of the company, the company is regular in depositing undisputed statutory dues including Goods and Services Tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues to the appropriate authorities. According to the information and explanation given to us there were no outstanding statutory dues as on 31st of March, 2022 for a period of more than six months from the date they became payable.
- (viii) According to the information and explanations given to us and on the basis of our examination of the records of the company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.
- (ix) (a) According to the information and explanations given to us and on the basis of our examination of the records of the company, the company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender. According to the information and explanations given to us and on the basis of our examination of the records of the company, the company has not been declared a willful defaulter by any bank or financial institution or other lender;



- (b) According to the information and explanations given to us by the management, the Company has not obtained any term loans during the year. Accordingly, clause 3(ix)(c) of the Order is not applicable.
- (c) According to the information and explanations given to us and on an overall examination of the balance sheet of the Company, we report that no funds raised on short term basis have been used for long term purposes by the company.
- (d) The Company does not hold any investment in any subsidiary, associate or joint venture (as defined under the Act) during the year ended 31 March 2022. Accordingly, clause 3(ix)(e) is not applicable.
- (e) The In our opinion and according to the information and explanations given by the management, the company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies. Accordingly, clause 3(ix)(f) is not applicable.
- (x) (a) The company has not raised any money by way of initial public offer or further public offer (including debt instruments) during the year. Accordingly, clause 3(x)(a) of the Order is not applicable.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) during the year. Accordingly, clause 3(x)(b) of the Order is not applicable.
- (xi) (a) Based on examination of the books and records of the Company and according to the information and explanations given to us , no fraud by the company or any fraud on the company has been noticed or reported during the course of audit.
- (b) According to the information and explanations given to us, no report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government;
- (c) According to the information and explanations given to us by the management, no whistle-blower complaints had been received by the company.



- (xii) The company is not a Nidhi Company. Accordingly, clause 3(xii)(a), 3(xii)(b) and 3(xii)(c) of the Order is not applicable.
- (xiii) In our opinion and according to the information and explanations given to us, all transactions with the related parties are in compliance with sections 177 and 188 of Companies Act, where applicable and the details have been disclosed in the financial statements, as required by the applicable accounting standards;
- (xiv) Based on information and explanations provided to us and our audit procedures, the company has an internal audit system commensurate with the size and nature of its business;
- (xv) In our opinion and according to the information and explanations given to us, the company has not entered into any non-cash transactions with directors or persons connected with him and hence, provisions of Section 192 of the Companies Act, 2013 are not applicable to the Company
- (xvi) (a) In our Opinion and based on our examination, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934 (2 of 1934). Accordingly, clause 3(xvi)(a) of the Order is not applicable.
- (b) In our Opinion and based on our examination, the Company has not conducted any Non-Banking Financial or Housing Finance activities without a valid Certificate of Registration (CoR) from the Reserve Bank of India as per the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable. ,
- (c) In our Opinion and based on our examination, the Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.
- (d) According to the information and explanations given by the management, the Group does not have any CIC as part of the Group.
- (xvii) Based on our examination, the company has not incurred cash losses in the financial year and in the immediately preceding financial year.
- (xviii) There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.



- (xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.
- (xx) Based on our examination, the provision of section 135 are not applicable on the company. Accordingly, clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable.
- (xxi) The company is not required to prepare Consolidate financial statement hence this clause is not applicable.

Place:-Delhi
Date: 05/09/2022
UDIN:22089919AXNUSK6717

For U.SHANKER & ASSOCIATES
Chartered Accountants
FRN: 0014497N

Uma Shanker Gupta
(Partner)

Membership No. 089919



Solitaire Drugs & Pharma Private Limited

304, Vikas Surya Shopping Mall, Manglam Place, Sector -3, Rohini, Delhi-110085

CIN: U24232DL2011PTC214744**Balance Sheet as on 31st March, 2022****₹ in hundred**

	Note No.	31st March, 2022 Amount (Rs.)	31st March, 2021 Amount (Rs.)
Equity and Liabilities			
Share Holder's Funds			
(a) Share Capital	3	23,830.00	23,830.00
(b) Reserves & Surplus	4	5,24,641.19	5,31,135.78
(c) Money received against share warrants		-	-
		<u>5,48,471.19</u>	<u>5,54,965.78</u>
Share application money pending allotment		-	-
Non Current Liabilities			
(a) Long-Term Borrowings	5	1,81,789.48	3,66,920.69
(b) Deferred Tax Liabilities (Net)	6	74,596.72	76,766.31
(c) Other long term liabilities		-	-
(d) Long-term provisions		-	-
		<u>2,56,386.20</u>	<u>4,43,687.00</u>
Current Liabilities			
(a) Short Term Borrowings	7	17,88,098.30	13,87,008.82
(b) Trade Payables	8	3,95,488.71	5,20,403.67
(c) Other Current Liabilities	9	1,40,108.23	2,63,515.97
		<u>23,23,695.24</u>	<u>21,70,928.46</u>
Total		<u><u>31,28,552.64</u></u>	<u><u>31,69,581.24</u></u>
Assets			
Non Current Assets			
(a) Property, Plant and Equipment and Intangible assets			
Tangible Assets	10	6,76,948.96	7,23,291.96
Intangible assets		-	-
Capital work-in-Progress		-	-
Intangible assets under development		-	-
(b) Long Term Loans & Advances	11	<u>9,558.27</u>	<u>7,928.71</u>
		<u>6,86,507.23</u>	<u>7,31,220.67</u>
Current Assets			
(a) Inventories	12	17,44,344.59	16,55,524.87
(b) Trade Receivable	13	5,22,904.13	6,13,917.65
(c) Cash & Cash Equivalents	14	7,352.73	48,924.22
(d) Short Term Loans & Advances	15	1,60,165.80	1,07,653.19
(e) Other Current Assets	16	<u>7,278.16</u>	<u>12,340.64</u>
		<u>24,42,045.41</u>	<u>24,38,360.57</u>
Total		<u><u>31,28,552.64</u></u>	<u><u>31,69,581.24</u></u>
The notes are integral part of the financial statements	1-28		

For and on behalf of the Board of Director


 Avnish Kumar Jain
 Director
 DIN : 00412597


 Sulabh Jain
 Director
 DIN : 03429718
 Place : New Delhi
 Dated: 5th September, 2022

As per our report of even date attached
For U.Shanker & Associates
 Chartered Accountants
 FRN: 014497N



CA Uma Shanker Gupta
 Partner
 Membership No. 089919
 UDIN No.:22089919AXNUSK6717


Solitaire Drugs & Pharma Private Limited


304, Vikas Surya Shopping Mall, Manglam Place, Sector -3, Rohini, Delhi-110085

CIN: U24232DL2011PTC214744**Statement of Profit & Loss for the year ended 31st March, 2022**

		31st March, 2022	₹ In hundred
	Note No.	Amount (Rs.)	31st March, 2021
			Amount (Rs.)
Income			
Revenue from Operations	17	34,02,886.89	21,75,310.53
Other Income	18	2,238.98	840.91
Total Income		<u>34,05,125.86</u>	<u>21,76,151.44</u>
Expenses:			
Cost of Material Consumed	19	22,64,617.81	15,58,080.70
Purchases of Finished Goods	20	6,50,936.02	4,89,969.48
Changes in Inventories	21	(75,406.78)	(4,20,165.27)
Direct Expenses	22	1,14,819.81	1,49,279.32
Employee Benefit Expense	23	43,102.18	42,120.11
Finance Cost	24	1,78,431.85	1,63,427.59
Depreciation	10	46,736.61	46,312.62
Other Expenses	25	1,23,834.70	1,03,294.25
Total Expenses		<u>33,47,072.20</u>	<u>21,32,318.81</u>
Profit before exceptional, extraordinary and prior period items and tax		58,053.67	43,832.63
Exceptional Items	26	48,717.08	-
Profit before tax		9,336.59	43,832.63
Tax Expense:			
Current Tax	18,000.77		11,532.23
Deferred Tax	(2,169.59)	15,831.18	28,992.95
Profit/ (Loss) for the period		<u>(6,494.59)</u>	<u>3,307.45</u>
Basic Earnings Per Equity Share	27	(2.73)	1.39
The notes are integral part of the financial statements	1-28		

For and on behalf of the Board of Director


 Avnish Kumar Jain
 Director
 DIN : 00412597


 Sulabh Jain
 Director
 DIN : 03429718
 Place : New Delhi
 Dated: 5th September, 2022

As per our report of even date attached
 For U.Shanker & Associates
 Chartered Accountants
 FRN: 014497N


 CA Uma Shanker Gupta
 Partner
 Membership No. 089919
 UDIN No.:22089919AXNUSK6717

Solitaire Drugs & Pharma Private Limited
Cash Flow Statement as on 31st March, 2022
₹ in hundred

Particulars	Amount (Rs.)	Amount (Rs.)
	2021-2022	2020-2021
A. Cash Flow from Operating Activities		
Profit Before Tax	9,336.59	43,832.63
Non Cash Adjustment		
Depreciation and amortization	46,736.61	46,312.62
Other Adjustments		
Interest Expenses	1,78,431.85	1,63,427.59
Interest & Other Income	(2,238.98)	(840.91)
Operating Profit before working Capital Changes	2,32,266.07	2,52,731.93
Increase / (Decrease) In Short Term Borrowings	4,01,089.48	39,254.94
Increase / (Decrease) In Trade Payables	(1,24,914.96)	1,89,173.28
Increase / (Decrease) In Other Current Liabilities	(1,23,407.74)	1,13,938.49
(Increase) / Decrease In Inventory	(88,819.72)	(4,11,543.24)
(Increase) / Decrease In Trade Receivables	91,013.53	(81,788.20)
(Increase) / Decrease In Short Term Loans And Advances	(52,512.61)	76,418.45
(Increase) / Decrease In Other Current Assets	5,062.48	1,669.12
Net Cash Flow from / (used in) Operating Activities (A)	3,39,776.52	1,79,854.77
B. Cash Flow from Investing Activities		
Purchase of Fixed Assets	(393.61)	(11,077.27)
(Increase) / Decrease In Long Term Investment	(1,629.56)	(328.71)
(Increase) / Decrease In Tax Provision	(18,000.77)	(11,532.23)
Interest & Other Income Received	2,238.98	840.91
Net Cash Flow from / (used in) Investing Activities (B)	(17,784.96)	(22,097.30)
C. Cash Flow From Financing Activities		
Interest Paid	(1,78,431.85)	(1,63,427.59)
Loan Taken / (Repayment) of Long Term Borrowing	(1,85,131.20)	27,226.12
Net Cash generated from / (used in) Financing Activities (C)	(3,63,563.05)	(1,36,201.47)
Net Increase / (decrease) in cash and cash equivalents (A+B+C)	(41,571.49)	21,556.00
Add : Cash & Cash Equivalents at the Beginning of the Period	48,924.22	27,368.22
Cash and Cash Equivalents at the end of the year	7,352.73	48,924.22
	0.00	0.00

Cash and Cash equivalent as per Balance Sheet
Bank - Balance with BOI- Kashipur
Axis Bank Ltd
Axis Bank Ltd- Kashipur
Axis Bank Ltd- Gurugram
Cash In Hand
Total
31st March, 2022
31st March, 2021
- 127.90
- 1,323.24
- 31,328.23
5.90 9,930.58
7,346.83 6,214.27
7,352.73 48,924.22
On Behalf of the Board
Avnish Kumar Jain
Director
DIN : 00412597
Sulabh Jain
Director
DIN : 03429718
Place : New Delhi
Dated: 5th September, 2022
As per our report of even date attached
For U.Shanker & Associates
Chartered Accountants & Associates
FRN: 014497N
CA U.S.Gupta
Partner
Membership No. 089919
UDIN No.:22089919AXNUSK6717

Solitaire Drugs &Pharma Private Limited

304, Vikas Surya Shopping Mall, Manglam Place, Sector - 3, Rohini, Delhi- 110085
CIN : U24232DL2011PTC214744, Email : ifreezefoods@gmail.com, Tel : 011-47501660

NOTES TO FINANCIAL STATEMENTS

As on March 31, 2022

1. **Corporate Overview:** The Company is mainly engaged in the agribusiness project of processing & preserving Fruits & Vegetables into frozen through Individual Quick Frozen (IQF) technology.

2. **Summary of Significant Accounting Policies:**

- 2.1 **Basis of Accounting**

The financial statements of the company are prepared in accordance the Generally Accepted Accounting Principles in India (Indian GAAP). The financial statements have been prepared on an accrual basis and under the historical cost convention. GAAP comprise applicable accounting standards specified under section 133 of the Companies Act 2013 red with Rule 7 of the Companies (Accounts) Rule 2014, other pronouncements of the Institute of Chartered Accountant of India, relevant applicable provision of the Companies act 2013. Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard required a change in the accounting policy hitherto in use. All asset and liabilities have been classified as current or non-current as per the company normal operating cycle and other criteria set out in the Schedule III to the Companies Act, 2013. The company has ascertained its operating cycle as 12 month for the purpose of current and non -current classification for assets and liabilities.

- 2.2 **Use of Estimates**

The preparation of the financial statement in conformity with generally accepted accounting principals in India requires management to make estimate and assumption that affect the reported amounts of revenue and expenses for the financial year, reported balances of assets and liabilities, and disclosure relating to contingent liabilities as at the date of the financial statements., The estimates and assumption used in the accompanying financial statements are based upon management/s evaluation of the relevant facts and circumstances as of the date of the financial statement. Actual results could differ from those estimates. Any revision to accounting estimates is recognized prospectively in current and future periods.

- 2.3 **Revenue Recognition**

Revenue from sale of goods is recognized on delivery of goods to the buyer which coincides with the transfer of all significant risks and rewards of ownership and is net of trade discount, sales returns and sales tax where applicable. Revenue from domestic sales is primarily recognized on dispatch basis. Revenue from services is recognized as per the term of contract with customers when the related services are performed.



Solitaire Drugs & Pharma Private Limited

304, Vikas Surya Shopping Mall, Manglam Place, Sector - 3, Rohini, Delhi- 110085
CIN : U24232DL2011PTC214744, Email : ifreezefoods@gmail.com, Tel : 011-47501660

NOTES TO FINANCIAL STATEMENTS (Cont.....)

As on March 31, 2022

2.4 Tangible Assets, Depreciation & Amortization

The fixed assets are stated at their original cost of acquisition / construction less accumulated depreciation for the year. Cost includes inward freight, duties, taxes and incidental expenses related to the acquisition and installation of the asset. Borrowing cost directly attributable to acquisition or construction of tangible assets, which necessary take a substantial period of time to be ready for their intended use, are capitalized. Depreciation on tangible assets is provided on a straight line method over the useful lives of the assets.

2.5 Impairment of Assets

The company Assesse at each Balance Sheet date whether there is any indication that an asset may be impaired. If any such indication exists the company estimates the recoverable amount of an asset. If such recoverable amount of the assets , or recoverable amount of the cash generating unit to which the assets belong is less than its carrying amount, the carrying amount is reduced to is recoverable amount. The reduction is treated as impairment loss and is recognized in the statement of Profit & Loss Account. If the balance sheet date there is an indication that a previously assessed impairment loss no longer exists, the recoverable amount is reassessed and the assets is reflected at the recoverable amount.

2.6 Foreign Currency Transaction.

During the year the company has received USD \$ 23,711.92 (Rs.17,26,227.78) from Govindas Gift Ltd, Mauritius against Export of goods .

2.7 Inventories

Inventories are valued at lower of cost or net realizable value. Raw material, packing materials valued at cost excluding vat & GST credits. In respect of finished goods cost includes raw material, packing material, labor cost and other appropriate allocable items. To arrive at the value of inventory as on 31.03.2022 (raw material, finished goods, consumables, spares, work in progress etc.) the company conducts a physical stock taking of all the materials available at plant in presence of plant manager, executives from the accounts department and directors in person.

2.8 Employees Benefits

Defined Contribution Plan : Contribution paid / payable under defined contribution plans are recognized in the statement of profit & loss account. Contribution plan in respect of ESIC and Employees Provident Fund are administered by the Government of India. The Company makes monthly contribution and has no further obligation under the plan beyond its contributors. No provision for retirement benefits has been made, as no employee has been put in the qualifying period of service for entitlement to the benefit. The necessary provisions for gratuity and retirement benefits will be made as and when applicable. The gratuity amounts will be booked as and when the payments are actually made.



Solitaire Drugs & Pharma Private Limited

304, Vikas Surya Shopping Mall, Manglam Place, Sector - 3, Rohini, Delhi- 110085

CIN : U24232DL2011PTC214744, Email : ifreezefoods@gmail.com, Tel : 011-47501660

NOTES TO FINANCIAL STATEMENTS (Cont.....)

As on March 31, 2022

2.9 Earning Per Share

The basic earnings per equity share are computed by dividing the net profit / loss attributable to the equity shares holders for the period by the weighted average numbers of equity shares outstanding during the reporting period.

2.10 Investments

The company does not hold any investment.

2.11 Contingent Liabilities & Provisions

As per AS-29, "Provisions, Contingent Assets and Contingent Liabilities", provisions involving substantial degree of estimation in measurement are recognised when there is a present obligation as a result of past events and it is probable that there will be an outflow of the resources. Contingent liabilities are not recognized but are disclosed as a foot note. Contingent assets are neither recognized nor disclosed in the financial statements.

2.12 Taxation

A. Current Tax

Provisions for current income tax liability is made on estimated Taxable Income under Income Tax Act, 1961 after considering permissible tax exemptions, deductions and disallowances, if any. This liability is calculated at the applicable tax rate. Minimum Alternative Tax (MAT) paid in accordance with tax laws, which give rise to future economic benefits in the form of adjustment of future income tax liability is considered as an asset. MAT credit entitlement is reviewed at each balance sheet date.

B. Deferred Tax

Deferred tax resulting from timing differences between book profits and tax profits is accounted for, at prevailing or substantially enacted rate of tax to the extent timing differences are expected to crystallize, in case of deferred tax liabilities with reasonable certainty and in case of deferred tax assets with virtual certainty supported with convincing evidences that, there will be adequate future taxable income against which such deferred tax assets can be realized.

2.13 Borrowing Cost

Interest and other borrowing costs charged to profit & loss account.

2.14 Government Grants: During the year the company has not received any Government Grants.

2.15 Cash & Cash Equivalents

The company considers all highly liquid financial instruments, which are readily convertible into cash and have original maturity of three months or less from the date of purchase, to be cash equivalents.



Solitaire Drugs & Pharma Private Limited

304, Vikas Surya Shopping Mall, Manglam Place, Sector - 3, Rohini, Delhi- 110085
CIN : U24232DL2011PTC214744, Email : ifreezefoods@gmail.com, Tel : 011-47501660

NOTES TO FINANCIAL STATEMENTS (Cont.....)

As on March 31, 2022

- 2.16 **Outstanding Balances** –Trade Receivables, Trade Payables, Advances to Customers / Suppliers and other Business Associates – The company has sent confirmation letters to all the parties to reconcile the outstanding balance as on 31.03.2022. However, in case confirmation is not received the company has reconciled the year end balances through telephonic and other communication with various parties.
- 2.17 In the opinion of the board, the Current Assets, Loans & Advances including Sundry Debtors are of the value as stated in the financial statements in the ordinary course of business. The provision of all known liabilities has been made.
- 2.18 **Security Deposits** –The Company has made certain security deposits with Uttarakhand Power Corporation Ltd. and Bharat Organics and Waste Management Ltd. These security amounts are being reconciled and recovery proceedings will be initiated.
- 2.19 The company has complied the applicable Accounting Standards as prescribed by the Central Government of India for the small companies.
- 2.20 **Cash Balance** - The Company is engaged in processing of agro based materials purchase from farmers directly. Therefore it maintains sizable cash balance (Rs.7,34,683.00 as on 31.03.2022) for its emergency needs at factory. Under the applicable laws, the company can utilise cash for purchasing agro based products directly from the farmers. The cash remains in the physical custody of the directors.
- 2.21 **TDS on Unsecured Loans taken From NBFCs** - As per the understanding with the lenders, TDS amount is not deducted from the interest payment installments. Interest is paid in full and to comply with income tax provisions TDS is also deposited separately. Due to this, there is double payment of TDS first in installments and thereafter separately. This amount is receivable from the lending NBFC companies. Amount of Rs. 4,21,266.00 is shown in balance sheet as receivable from NBFC companies on account of TDS deposited on their behalf.
- 2.22 **Stock transfer** - Goods transferred from factory to Delhi godown are not included in sales, however as per GST provisions, this is to be considered as Sale and applicable GST is paid by the company through tax invoices. Similarly stock transferred from Delhi Godown to Factory is also considered as Sale for GST purpose and applicable taxes are paid through tax invoices.

Stock Transfers (01.04.2021 to 31.03.2022)	Amount (Rs)
From Plant – Kashipur, Uttarakhand to Delhi Godown (IGST)	1,87,31,921.00
From Delhi Godown to Plant – Kashipur, Uttarakhand Godown (IGST)	14,47,650.21
Total	2,01,79,571.21



Solitaire Drugs & Pharma Private Limited

304, Vikas Surya Shopping Mall, Manglam Place, Sector - 3, Rohini, Delhi- 110085
CIN : U24232DL2011PTC214744, Email : ifreezefoods@gmail.com, Tel : 011-47501660

NOTES TO FINANCIAL STATEMENTS (Cont.....)


As on March 31, 2022

- 2.23 The company has reversed proportionate G.S.T input received due to maximum sale are exempted as per GST Act. The GST reversal amount of prior period from 01.07.2017 to 31.03.2021 is Rs.48,71,708.00 and during the period 01.04.2021 to 31.03.2022 is Rs. 10,23,682.22.
- 2.24 Earning in foreign currency : USD 23711.92
- 2.25 Expenditure in foreign currency. : NIL
- 2.26 Earning & expenditure in respect of employees who were in receipt of remuneration aggregating to
- a) Not less than Rs. 30,00,000/- per annum. : NIL
- b) Not less than Rs. 250,000/- per month, if employed for part of the year. : NIL
- 2.27 Previous year figures have been regrouped & re-arranged wherever necessary to correspond with the current year's classification / disclosures.

Notes to financial statements form integral part of these financial statements.

For and on behalf of the Board of Director


Avnish Kumar Jain
Director
DIN: 00412597


Sulabh Jain
Director
DIN: 03429718
Place: New Delhi
Dated: 5th September, 2022

For U.Shanker & Associates,
Chartered Accountants
F. R. No. 014497N



CA Uma Shanker Gupta
(Partner)
Membership No. 089919
UDIN No.:22089919AXNUSK6717

Solitaire Drugs & Pharma Private Limited
CIN: U24232DL2011PTC214744
Notes to the Financial Statements 31st March, 2022

₹ in hundred

3 Share Capital

<u>Particulars</u>	<u>Opening Balance</u>	<u>Additions</u>	<u>Reductions</u>	<u>Closing Balance</u>
(a) Authorised Share Capital 300000 shares of Rs. 10 each	30,000.00	-	-	30,000.00
(b) Issued, Subscribed & Paid up 238300 shares of Rs. 10 each	23,830.00	-	-	23,830.00
(c) Paid up Share Capital 238300 shares fully paid up Rs. 10/- each	23,830.00	-	-	23,830.00

II Shares in the Company held by each shareholder holding more than 5% shares

Name of shareholder	<u>31st March, 2022</u>		<u>31st March, 2021</u>	
	Number of shares	% Holding	Number of shares	% Holding
a) Mr. Avnish Kumar Jain	32,100	13.47	32,100	13.47
b) Mr. Sulabh Jain	86,600	36.34	50,000	20.98
c) Mrs. Mukta Jain	-	-	36,600	15.36
d) A.K. Jain (HUF)	25,000	10.49	25,000	10.49
e) M/s Solitaire Infracon Pvt Ltd	62,000	26.02	62,000	26.02
c) Mrs. Kusum Jain	22,600	9.48	22,600	9.48

III Details of Shares held by Promoters

Name of shareholder	<u>31st March, 2022</u>		<u>31st March, 2021</u>	
	Number of shares	% Holding	Number of shares	% Holding
a) Mr. Avnish Kumar Jain	32,100	13.47	32,100	13.47
b) Mr. Sulabh Jain	86,600	36.34	50,000	20.98
c) Mrs. Mukta Jain	-	-	36,600	15.36

4 Reserves & Surplus

<u>Particulars</u>	<u>31st March, 2022</u> <u>Amount (Rs.)</u>	<u>31st March, 2021</u> <u>Amount (Rs.)</u>
<u>(A) Securities Premium</u>		
Opening Balance	3,46,140.00	3,46,140.00
Closing Balance	<u>3,46,140.00</u>	<u>3,46,140.00</u>
<u>(B) Surplus</u>		
Opening Balance	1,84,995.78	1,81,688.33
Add : Profit/(Loss) for the year	<u>(6,494.59)</u>	<u>3,307.45</u>
Total	<u>1,78,501.19</u>	<u>1,84,995.78</u>
Total (A+B)	<u>5,24,641.19</u>	<u>5,31,135.78</u>

[Signature]



	31st March, 2022 Amount (Rs.)	31st March, 2021 Amount (Rs.)
5 Long -Term Borrowings		
<u>Secured Loan</u>		
<u>From Banks</u>		
Working Capital Term Loan - Axis Bank- 48674**	-	92,000.00
W.C.Term Loan ECLGS- Axis Bank- 7497**	-	1,68,750.00
Term Loan -Axis Bank - 24720**	-	9,300.00
Term Loan - Axis Bank - 24678**	-	18,962.00
W.C.Term Loan - ECLGS Bank of India - 46**	1,14,000.00	-
W.C.Term Loan ECLGS- Bank of India- 17**	44,000.00	-
<u>Unsecured Loan Business Loan #</u>		
Deutsche Bank AG	-	4,870.00
ECL Finance Ltd	-	7,524.01
Fullerton India Credit Co Ltd	-	11,503.54
IDFC First Bank - 27972986	-	12,149.94
Tata Capital Loan Ltd	10,167.73	22,369.09
Fullerton India Credit Co Ltd (ECLGS)	3,461.48	5,625.01
IDFC First Bank - (ECLGS)	4,483.86	7,503.16
Kotak Mahindra Ltd - (ECLGS)	3,009.51	2,504.97
Magma Fincorp Limited (ECLGS)	2,666.90	3,858.96
Total	1,81,789.48	3,66,920.69

** These term loans is received from Bank of India and these are secured by hypothecation of stocks and receivables of the company and equitable mortgage of factory land, building & plant & machinery situated at Plot No. 439 & 440, Shree Developers, Industrial Estate, Mahua Khera Ganj, Kashipur, Uttarakhand and personal guarantees of directors of the company Mr. Avnish Kumar Jain, Mr. Sulabh Jain & Corporate Guarantee by M/s Solitaire Infracon (P) Ltd.

These loans are only secured by the personal gurantees of the directors. The portion of loans which is payable in next 12 months from the date of Balance Sheet is classified as Current maturities of long term borrowings. Loan payable after this period is shown under long term borrowings.

6 Deffrred Tax Liability (NET)		
Opening Balance of Timing Difference	2,95,255.02	1,83,743.70
<u>Add: Creation of Timing Difference</u>		
(a) On Depreciation (WN-1)	(8,344.55)	(2,190.45)
Add: Reversal of Timing Difference (DTA) earlier	-	1,13,701.77
Closing Balance of Timing Difference	2,86,910.47	2,95,255.02
 Deferred Tax Liability @ 26% - shown in Balance Sheet	74,596.72	76,766.31
Opening Balance	76,766.31	47,773.36
DTL to be transferred to P & L	(2,169.59)	28,992.95
 <u>Calculation of Timing Difference on Depreciation</u>		
Depreciation as per Income Tax Act	38,392.06	44,122.17
Depreciation as per Companies Act	46,736.61	46,312.62
	(8,344.55)	(2,190.45)

Handwritten signature



	31st March, 2022 Amount (Rs.)	31st March, 2021 Amount (Rs.)
7 Short -Term Borrowings		
<u>I. Secured Loan</u>		
<u>From Banks</u>		
Working Capital Loan from Axis Bank Ltd *	-	9,91,258.82
Working Capital Loan from Bank of India- 87 *	11,96,694.01	-
Working Capital Loan from Bank of India- 104*	6,703.29	-
Total - I	12,03,397.30	9,91,258.82
<u>II. Unsecured Loans</u>		
<u>From Directors & Directors Relatives</u>		
Avnish Kumar Jain	2,84,901.00	2,56,950.00
Sulabh Jain	27,000.00	27,000.00
Mukta Jain	2,04,000.00	43,000.00
Kusum Jain	44,000.00	44,000.00
Shagun Jain	24,800.00	24,800.00
Total - I	5,84,701.00	3,95,750.00
Total - I + II	17,88,098.30	13,87,008.82
Notes:		

* The above loan received from Bank of India is also secured by hypothecation of stocks and receivables of the company and equitable mortgage of factory land, building & plant & machinery situated at Plot No. 439& 440, Shree Developers, Industrial Estate, Mahua Khera Ganj, Kashipur, Uttarakhand. The above loan is further secured by personal guarantees of directors of the company, Mr. Avnish Kumar Jain, Mr. Sulabh Jain, and Corporate Guarantee by M/s Solitaire Infracon (P) Ltd.

8 Trade Payable		
<u>Sundry Creditors</u>		
MSME	-	-
Others	1,01,357.92	2,25,897.69
<u>Advances from Customers</u>		
MSME	-	-
Others	2,94,130.79	2,94,505.98
Total	3,95,488.71	5,20,403.67
Outstanding for following periods from due dates of payments:		
a) Less than one year	3,84,742.70	5,08,705.02
b) Less than two year	6,471.34	2,201.41
c) Less than three years	-	-
d) More than three years	4,274.67	9,497.24

9 Other Current Liabilities		
<u>Current maturities of long term borrowings **</u>		
Working Capital Loan - Axis Bank- 48674	-	48,000.00
W.C.Term Loan ECLGS- Axis Bank- 7497	-	58,017.64
Term Loan -Axis Bank - 24720	-	7,200.00
Term Loan - Axis Bank - 24678	-	8,748.00
W.C.Term Loan - Bank of India- 17**	48,000.00	-
Vehicle loan - HDFC Bank Ltd- 4037***	-	1,756.66
Vehicle loan - HDFC Bank Ltd -4407***	-	811.60
Vehicle loan - HDFC Bank Ltd.-3021***	-	1,691.71
Vehicle loan - HDFC Bank Ltd. -4114***	-	631.48



Solitaire Drugs & Pharma Private Limited
CIN: U24232DL2011PTC214744
Notes to the Financial Statements 31st March, 2022

₹ In hundred
31st March, 2021
Amount (Rs.)

31st March, 2022
Amount (Rs.)

Unsecured Business Loan #

Axis Bank Ltd	-	10,092.85
Deutsche Bank AG	4,846.04	15,206.04
ECL Finance Ltd	7,524.01	8,579.73
Fullerton India Credit Co Ltd	11,503.54	11,883.20
IDFC First Bank Ltd - 27972986	12,149.94	14,042.78
IDFC First Bank Ltd -19094727	-	3,525.35
Kotak Mahindra Bank Ltd	-	17,915.93
Magma Fincorp Limited	-	9,031.38
Tata Capital Loan Ltd	12,201.36	12,201.36
Fullerton India Credit Co Ltd (ECLGS)	2,163.53	1,222.99
IDFC First Bank - (ECLGS)	3,019.30	1,863.71
Kotak Mahindra Ltd - (ECLGS)	2,200.94	740.03
Magma Fincorp Limited (ECLGS)	1,192.02	183.03

Other Payables

Electricity Expenses	17,610.62	14,252.85
Salary Payable	2,329.80	3,347.34
Director Remuneration Payable	-	2,694.00
TDS	1,811.31	636.79
TCS	289.70	352.52
Auditor's Remuneration	1,350.00	1,387.50
ESIC	42.80	52.78
EPF	311.20	384.94
GST- Kashipur Payable	1,412.08	-
Office Rent	-	277.50
Income Tax Payable	10,150.04	6,784.30
Total	1,40,108.23	2,63,515.97

** These term loans are received from Bank of India and these are secured by hypothecation of stocks and receivables of the company and equitable mortgage of factory land, building & plant & machinery situated at Plot No. 439 & 440, Shree Developers, Industrial Estate, Mahua Khera Ganj, Kashipur, Uttarakhand. and personal guarantees of directors of the company Mr. Avnish Kumar Jain, Mr. Sulabh Jain & Corporate Guarantee by M/s Solitaire Infracon (P) Ltd.

***These vehicle loans are received from HDFC Bank Ltd. These loans are secured by the hypothecation of the financed vehicle. The portion of the vehicles loans which is payable in next 12 months from the date of Balance Sheet is classified as Current maturities of long term borrowings. Loan payable after this period is shown under long term borrowings.

The portion of the loans which is payable in next 12 months from the date of B/S is shown as Current maturities of long term borrowings in other Current Liabilities.

11 Long Term Loans & Advances

Security Deposit - B.O. & W.M.Ltd.	1,000.00	1,000.00
Electricity Security Deposit - UPCL	8,458.27	6,828.71
Hotel Security (Claridges Hotel P. Ltd.)	100.00	100.00
Total	9,558.27	7,928.71

12 Inventories

- Raw Materials	20,018.39	12,141.05
- Consumable Store	24,137.66	18,602.06
Stock in Trade		
- Finished Goods	17,00,188.54	16,24,781.76
Total	17,44,344.59	16,55,524.87

[Signature]



Solitaire Drugs & Pharma Private Limited

Note No. - 10

Tangible Assets- (Fixed Assets) as at 31st March, 2022 (As per Companies Act, 2013)

in hundred

Particular	Original Cost (Rs)	Gross Block			Depreciation / Amortisation and Depletion			Net Block	
		As at 01.04.2021	Additions/ Adjustments	Deductions/Adj ustment	As at 01.04.2021	For the Year	Deductions /Adjustmen	WDV as at 31st Mar 2022	WDV as at 31st Mar 2021
Factory Land & Development	1,37,125.07	1,37,125.07	-	-	-	-	-	1,37,125.07	1,37,125.07
Plant & Machinery	8,46,660.61	5,60,446.42	-	-	2,02,379.77	34,560.20	-	3,23,506.45	3,58,066.65
Factory Building	3,79,050.98	2,68,543.57	-	-	58,543.70	8,315.91	-	2,01,683.96	2,09,999.87
Printer	157.00	157.00	-	-	149.15	-	-	7.85	7.85
Generator	2,156.50	2,156.50	-	-	2,048.67	-	-	107.83	107.83
Refrigerator- 1	315.00	315.00	-	-	299.25	-	-	15.75	15.75
Refrigerator- 2	305.00	305.00	-	-	289.75	-	-	15.25	15.25
Bar Code Printer	180.60	180.60	-	-	171.57	-	-	9.03	9.03
Car - Maruti Swift	5,862.08	5,862.08	-	-	5,568.98	-	-	293.10	293.10
Tata- 407	6,050.00	6,050.00	-	-	3,554.80	718.44	-	1,776.76	2,485.20
Tata- 407 (Body)	1,890.00	1,890.00	-	-	846.11	224.44	-	819.45	1,043.89
Chest Freezer	228.90	228.90	-	-	157.87	43.49	-	27.54	71.03
UPS	42.37	42.37	-	-	28.69	8.05	-	5.63	13.68
Chest Freezer	221.09	221.09	-	-	146.06	42.01	-	33.02	75.03
Chest Freezer	242.19	242.19	-	-	157.60	46.02	-	38.57	84.59
Tata- 709	13,188.70	8,638.70	-	-	3,369.33	997.41	-	4,271.96	5,269.37
UPS	27.97	27.97	-	-	17.91	5.31	-	4.75	10.06
Bar Code Printer	41.53	41.53	-	-	24.92	7.89	-	8.72	16.61
Maxi Bolero	4,869.14	4,869.14	-	-	1,736.21	578.21	-	2,554.72	3,132.93
Maxi Bolero-Body	3,700.00	3,700.00	-	-	1,296.47	439.38	-	1,964.15	2,403.53
Motor Cycles	565.92	565.92	-	-	159.51	53.76	-	352.65	406.41
Deep Freezer	313.56	313.56	-	-	158.82	59.58	-	95.16	154.74
Deep Fryer	76.27	76.27	-	-	38.39	14.49	-	23.39	37.88
Plant Furniture	291.00	291.00	-	-	122.24	55.29	-	113.47	168.76
Printer	76.27	76.27	-	-	32.79	14.49	-	28.99	43.48
Printer	165.25	165.25	-	-	66.59	31.40	-	67.26	98.66
Printer	100.00	100.00	-	-	29.10	19.00	-	51.90	70.90
Weight Machine	29.50	29.50	-	-	8.56	5.60	-	15.34	20.94
Printer	45.00	45.00	-	-	12.95	8.55	-	23.50	32.05
Printer	254.24	254.24	-	-	72.00	48.31	-	133.93	182.24
R.O	103.60	103.60	-	-	26.42	19.68	-	57.50	77.18
Air Conditioner	500.00	500.00	-	-	82.25	95.00	-	322.75	417.25
Cooler	253.00	253.00	-	-	39.64	48.07	-	165.29	213.36
Laptop	630.00	630.00	-	-	57.72	119.70	-	452.58	572.28
GC TV	568.68	568.68	-	-	29.67	108.04	-	430.97	539.01
Printer	393.61	393.61	-	-	-	48.89	-	344.72	-
Grand Total	14,06,287.02	10,05,015.42	393.61	-	2,81,723.46	46,736.61	-	6,76,948.96	7,23,291.96
Previous Year	14,06,287.02	9,93,938.15	11,077.27	-	2,81,723.46	46,312.62	-	7,23,291.96	7,58,527.31

Depreciation has been provided on Straight Line Method
For and on behalf of the Board of Director


Avnish Kumar Jain
Director
DIN : 00412597


Sulabh Jain
Director
DIN : 03429718

Dated: 5th September, 2022
Place: New Delhi

As per our report of even date attached
For U.Shanker & Associates
Chartered Accountants
FRN: 014497N


CA Uma Shanker Gupta
Partner
Membership No. 089943

Solitaire Drugs & Pharma Private Limited
CIN: U24232DL2011PTC214744
Notes to the Financial Statements 31st March, 2022

13 Trade Receivable (Unsecured,
Considered Good unless stated
Debts overdue for a period exceeding six
months from the due date

- Considered good
- Doubtful

Others Debts

- Considered good
- Doubtful

Total

31st March, 2022
Amount (Rs.)

₹ In hundred
31st March, 2021
Amount (Rs.)

1,16,808.01

1,45,362.39

-

-

4,06,096.11

4,68,555.26

-

-

5,22,904.13

6,13,917.65

Debts overdue for following periods exceeding from due dates of payments:
(Unsecured, Considered Good)

- a) Less than six months
- b) Less than one year
- c) Less than two year
- d) Less than three years
- e) More than three years

4,06,096.11

4,68,555.26

18,467.81

3,845.24

3,924.58

56,280.56

25,577.73

29,789.61

68,837.89

55,446.98

14 Cash & Cash Equivalents

Bank - Balance with BOI- Kashipur

-

127.90

Axis Bank Ltd

-

1,323.24

Axis Bank Ltd- Kashipur

-

31,328.23

Axis Bank Ltd- Gurugram

5.90

9,930.58

Cash In Hand

7,346.83

6,214.27

Total

7,352.73

48,924.22

15 Short Term Loans & Advances

Advance to Suppliers (Unsecured, Considered Good)

1,08,724.58

14,560.76

Balances with Revenue Authority

GST- Delhi

10,889.31

18,104.27

GST- Kashipur

475.34

29,538.80

GST - Delhi Receivable

235.81

56.52

GST - Kashipur Receivable

386.69

491.56

I. T. Refund Due. A. Y. 13-14 *

141.90

141.90

MAT Credit F. Y. - 2015-16

-

3,275.72

MAT Credit F. Y. - 2016-17

2,666.34

5,410.16

MAT Credit F. Y. - 2017-18

7,845.82

7,845.82

MAT Credit F. Y. - 2018-19

10,932.21

10,932.21

MAT Credit F. Y. - 2019-20

10,713.88

10,713.88

Prepaid Expenses

Licence Fees

3,246.40

3,782.25

Insurance - Plant

3,651.33

2,537.26

Insurance - Vehicles

256.19

262.08

Total

1,60,165.80

1,07,653.19

16 Other Current Assets

Staff Advance

-

1,941.39

TDS Receivable - (Parties)

4,212.66

2,977.18

Gold Bond

2,115.50

2,115.50

FDR with Bank

-

5,306.57

Service Tax

950.00

-

Total

7,278.16

12,340.64



Solitaire Drugs & Pharma Private Limited
CIN: U24232DL2011PTC214744
Notes to the Financial Statements 31st March, 2022
₹ in hundred

	31st March, 2022 Amount (Rs.)	31st March, 2021 Amount (Rs.)
17 Revenue From Operations		
Sales - Kashipur, Uttarakhand *	31,43,713.12	19,37,881.81
Exoprt - Kashipur, Uttarakhand *	17,215.75	42,663.55
Sales - Delhi *	2,41,958.02	1,94,765.17
Total	34,02,886.89	21,75,310.53
* Sales are excluded transferred of goods from plant kashipur uttarakhand to delhi godown Rs.1,87,31,921.00 and delhi to plant kashipur uttarakhand Rs. 14,47,650.21 However as per GST provisions, this is to be considered as Sale and applicable GST is paid by the company through Tax Invoices.		
18 Other Income		
Interest Income	2,027.09	775.61
Misc Income	211.88	65.30
Total	2,238.98	840.91
19 Cost of Material Consumed		
<u>Raw Material Consumed</u>		
Opening Stock	12,141.05	21,244.77
Add: Purchases	22,25,104.53	14,87,328.88
Total	22,37,245.58	15,08,573.65
Less: Closing Stock	20,018.39	12,141.05
Total (a)	22,17,227.20	14,96,432.60
<u>Packing and other Components Consumed</u>		
Opening Stock	18,602.06	18,120.37
Add: Purchases	52,926.22	62,129.79
Less: Closing Stock	24,137.66	18,602.06
Total (b)	47,390.61	61,648.10
Total Cost of Material Consumed (a+b)	22,64,617.81	15,58,080.70
20 Purchase Finished Goods		
Purchase Finished/Traded Goods - Kashipur	6,46,798.39	4,89,969.48
Purchase Traded Goods - Delhi	4,137.63	-
Total	6,50,936.02	4,89,969.48
21 Changes In Inventory of Finished Goods		
(Increase / (Decrease in Inventory)		
<u>Closing Inventory</u>		
Finished Goods	17,00,188.54	16,24,781.76
<u>Opening Inventory</u>		
Finished Goods	16,24,781.76	12,04,616.49
(Increase) / Decrease in Inventory	(75,406.78)	(4,20,165.27)
22 Direct Expenses		
Power & Fuel	1,03,184.34	1,11,913.30
Repair of Plant & Machinery	7,361.75	9,775.63
Repair of Factory Building	-	1,614.65
Jobwork Charges Paid	4,273.72	25,975.74
Total	1,14,819.81	1,49,279.32
23 Employee Benefits Expenses		
Salary & Wages	39,206.53	38,412.66
Staff Welfare	1,153.55	1,065.07
EPF Exp	2,334.80	2,132.44
ESI Exp.	407.30	509.94



Solitaire Drugs & Pharma Private Limited
CIN: U24232DL2011PTC214744
Notes to the Financial Statements 31st March, 2022

	31st March, 2022 Amount (Rs.)	₹ In hundred 31st March, 2021 Amount (Rs.)
24 Finance Cost		
Interest on Term Loan	2,362.27	19,652.12
Interest on Working Capital Loan	1,17,479.46	1,02,509.43
Interest on Business Loan	21,954.38	35,427.97
Processing & Other Charges	36,412.23	5,146.67
Interest on Vehicle Loan	223.51	691.41
Total	1,78,431.85	1,63,427.59
25 Other Expenses		
Bank Charges	313.77	218.74
Businss Promotion	604.25	553.33
Bad Debts	2,789.80	-
GST Input Reversal	13,217.08	-
Commisson Paid	11,538.30	13,061.94
Conveyance	666.00	645.18
Consultancy & Professional Services	6,217.70	9,693.84
Director Remuneration	20,400.00	20,400.00
Electricity - Office	3,234.26	1,947.83
Factory Expenses	2,569.72	2,348.46
Security Gurad Expenses	5,342.26	5,761.94
Freight Paid	7,153.84	5,286.51
Ocean Freight & Forwarding Charges	3,502.70	4,649.65
Insurance - Plant	2,672.10	2,637.17
Insurance - Vehicle	542.66	582.44
Interest & Late Fees Charges	1,739.76	2,654.83
License Fees	4,084.85	681.00
Vehicle Running Exp.	19,017.38	15,606.92
Internal Audit Fee	110.00	100.00
Rent	5,220.00	5,425.00
Miscellaneous Expenses	3,354.93	3,216.78
Maintenance Charges	1,014.41	1,014.41
Printing & Stationery	323.72	127.08
Storage Charges	3,633.70	4,356.07
Rebate & Discount	1,881.29	356.43
Auditors Remuneration	1,500.00	1,500.00
Telephone Expenses	384.24	468.71
ROC Expenses	806.00	-
Total	1,23,834.70	1,03,294.25
26 Exceptional Items		
Proportionate revesal of Goods & Service Tax input received for the prior period 01.07.2017 to 31.03.2021 due to exempted sale	48,717.08	-
	48,717.08	-
27 Basic Earning Per Share		
Earnings available for equity shareholders - (A)	(6,494.59)	3,307.45
Number of equity shares - (B)	238300	238300
Basic Earnings Per Share (Face Value Rs. 10/-) in Rs.	(2.73)	1.39



28 Related Party Disclosures as required by Accounting Standard - AS 18

A Names of related parties:

Description of Relationship	Name of the Party
Where significant influence exists	Solitaire Infracon Pvt. Ltd.
Key Management Personnel	Mr. Avnish Kumar Jain Mr. Sulabh Jain Mrs. Mukta Jain
Related Party	Mrs. Kusum Jain Mrs. Shagun Jain

B Summary of transactions with related party

in hundred

Party Name	Amount (Rs.)
Key Management Personnel	
Avnish Kumar Jain	Directors Remuneration 12,000.00 Rent 3,600.00 Loan (Received) 27,951.00 Loan (Returned) - Rembursment Dues 7,575.78 Rembursment Paid 7,575.78
Sulabh Jain	Directors Remuneration 8,400.00
Mukta Jain	Loan (Received) 1,61,000.00 Loan (Returned) -
Kusum Jain	Loan (Received) 8,500.00 Loan (Returned) 8,500.00


C Outstanding Balances of Related Parties is as follows:

in hundred

	Amount (Rs.)
Mr. Avnish Kumar Jain	2,84,901.00
Mr. Sulabh Jain	27,000.00
Mrs. Mukta Jain	2,04,000.00
Mrs. Kusum Jain	44,000.00
Mrs. Shagun Jain	24,800.00

Note: The above information has been determined to the extent such parties have been identified on the basis of information provided by the Company and approved by the Board of Directors of the Company, which has been relied upon by the Auditors.

For and on behalf of the Board of Director


Avnish Kumar Jain
Director
DIN : 00412597


Sulabh Jain
Director
DIN : 03429718

Place : New Delhi
Dated: 5th September, 2022

As per our report of even date attached
For U. Shanker & Associates
Chartered Accountants
FRN: 014497N

CA Uma Shanker Gupta
Partner
Membership No. 089919
UDIN No.:22089919AXNUSK6717

Solitaire Drugs & Pharma Private Limited

304, Vikas Surya Shopping Mall, Manglam Place, Sector -3, Rohini, Delhi-110085

CIN: U24232DL2011PTC214744**Note number: 28- D Additional Regulatory Information**


Ratios:

S.No	Ratio	Numerator	Denominator	Current Year Ratio	Previous Year Ratio	% Change	Reason for variance
a	Current Ratio	Current Assets	Current Liabilities	1.05	1.12	(6.25)	-
b	Debt-Equity Ratio	Long Term Debt + Short Term Debt	Shareholder equity	3.78	3.58	5.59	-
c	Debt Service Coverage Ratio	Earning Before Interest, tax, Depreciation & Amortisation	Total principal + Interest on Borrowings	1.00	0.64	56.25	C.Y term loans insallment has decreased as compared to P.Y
d	Return on equity ratio	Earning After Interest, tax, Depreciation & Amortisation	Average Shareholder's Equity	(0.01)	0.01	(200.00)	Due to Loss after tax in Current year
e	Inventory turnover ratio	Turnover	Average Inventory	2.00	1.50	33.33	Increased in turnover in C.Y
f	Trade Receivables turnover ratio	Net Credit Sales	Average Trade Receivable	5.99	3.80	57.70	Increased in turnover in C.Y
g	Trade payables turnover ratio	Net Credit Purchase	Average Trade Payable	6.40	4.79	33.54	Increased in purchased in C.Y
h	Net capital turnover ratio	Total Sales	Average Working Capital	17.64	9.88	78.59	Increased in total sales in C.Y
i	Net profit ratio*	Net Profit	Net Sales	(0.19)	0.15	(226.67)	Due to Loss after tax in Current year
j	Return on Capital employed	Earning Before Interest & tax	Capital employed**	11.89	10.64	11.69	-
k	Return on investment	Net/ (Loss) Profit after tax	Net Assets	(0.01)	0.01	(200.00)	Due to Loss after tax in Current year

* Net profit ratio is calculate in percentage

** Capital employed means is paid up capital of the company

For and on behalf of the Board of Director



Avnish Kumar Jain
Director
DIN : 00412597



Sulaab Jain
Director
DIN : 03429718
Place : New Delhi
Dated: 5th September, 2022

As per our report of even date attached

For U.Shanker & Associates

Chartered Accountants

FRN: 014497N



CA Uma Shanker Gupta
Partner

Membership No. 089919

UDIN No.:22089919AXNUSK6717